About a third of lung transplant patients with cystic fibrosis receive elexacaftor-tezacaftor-ivacaftor; use is higher among ...

In July 2025, Vertex Pharmaceuticals Incorporated conducted a study is to evaluate the pharmacokinetics, safety, tolerability ...

First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting ...

NHS England » NHS to roll-out new ‘triple combination’ therapy for hundreds of children and adults with cystic fibrosis ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

Individuals with cystic fibrosis or CFTR gene variants have a 3-fold higher risk of developing pancreatic cancer after 50 years of age.

The NHS will offer a once-daily triple therapy for cystic fibrosis to hundreds more patients, including those with rare ...

Electromed, Inc. (NYSE:ELMD) is one of the 11 Best Long Term Low Risk Stocks to Invest in. Analysts maintain a Buy rating ...

Investing.com -- BiomX (NYSE: PHGE) Inc. (NYSE American:PHGE) stock surged 60% after the clinical-stage company announced it has successfully initiated patient dosing in its Phase 2b trial evaluating ...

BiomX has published promising phase 1b/2a trial results in Nature Communications, demonstrating that its phage cocktail BX004 ...

BiomX Inc. (AMEX:PHGE) saw its stock jump 60% after announcing the commencement of patient dosing in its Phase 2b clinical ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...